Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.
Also called NCT03469349
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 366 participants
- Sponsor
- Registry
-
NCT03469349 -
2017-004741-24
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Georgia, Kazakhstan, Russia
- Registry status
- Completed
Technical summary
Registry record NCT03469349. Randomized; double masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2019-05-28 (actual). Results posted on 2020-10-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
- Acronym
- APOLLO
- Condition
- Peripheral Arterial Diseases
- Intervention (Drug)
- Actovegin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct03469349- Content hash
5e9e3a425b4eda5357935ee0c584d8d37bdf5e2e8abdad2215f54bdbc2e76039